What to Know About Marty Makary, Trump's Pick to Lead FDA
In this image from video provided by the Committee on Oversight and Government Reform, Dr. Martin Makary speaks during a select subcommittee on the coronavirus pandemic roundtable in Washington on Feb. 28, 2023. Credit - Committee on Oversight and Government Reform/AP
President Donald Trump nominated Dr. Marty Makary to lead the U.S. Food and Drug Administration (FDA), the federal agency tasked with ensuring the safety and efficacy of drugs, medical devices, food, and cosmetics.
Makary, a surgical oncologist at Johns Hopkins University, will appear before the Senate Committee on Health, Education, Labor and Pensions on Thursday, March 6 for his nomination hearing. If confirmed by the Senate, he would run one of the country's leading health agencies, overseeing the regulation of products ranging from vaccines to abortion medications.
Here's what to know about Makary.
Makary serves as the chief of islet transplant surgery at the Johns Hopkins School of Medicine. Much of his research has focused on the underlying causes of disease and the cost of health care. He's also a member of the National Academy of Medicine.
Makary initially expressed support for lockdown restrictions and masking early on in the COVID-19 pandemic. But later, he made regular appearances on Fox News, where he opposed COVID-19 vaccine mandates.
Dr. Paul Offit, director of the vaccine education center at Children's Hospital of Philadelphia and a member of the FDA's vaccine advisory committee, says that we shouldn't have had to mandate the COVID-19 vaccine, but it made sense to do so during a global pandemic.
'In a better world, a world in which we do not live, anybody who looked at the data for those vaccines would have gotten the vaccine,' Offit says.
'Hospitals were being overrun. We had nurses wearing bandanas for masks. We had nurses wearing garbage bags for gowns,' he continues. 'You shouldn't have had to have mandated vaccines, but it just seemed like a perfectly reasonable thing to do at the time to try and increase vaccine rates.'
Some estimates suggest that, in the first five months of vaccine availability, COVID-19 vaccines saved nearly 140,000 lives in the U.S.
While Makary has not publicly aligned himself with the anti-COVID-19- vaccine views that his would-be boss, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., has shared, he accused public-health officials in former President Joe Biden's Administration of 'instituting a vaccine mandate that ignored natural immunity.' In an opinion piece for the Wall Street Journal published in Feb. 2021, Makary argued that the U.S. was moving toward herd immunity, predicting that 'COVID will be mostly gone by April, allowing Americans to resume normal life.' Months after the piece was published, COVID-19 cases surged as the Delta variant spread across the country. Soon after, in the winter, the Omicron variant tore through the nation, leading to another spike in cases. Thousands of people died during the surges.
If confirmed to lead the FDA, Makary would oversee the regulation of the country's vaccine supply. At the end of February, members of the FDA's vaccine advisory committee learned that a meeting on March 13 to decide on the influenza strains that would be included in the next flu shot was canceled. The meeting has been held every year since the late 1960s. Offit says he hopes that Makary, at Thursday's nomination hearing, will say he values external, expert advisors, like those on the vaccine advisory committee.
Makary shares many of the same views on food that Kennedy and his 'Make America Healthy Again' movement do. He has suggested that chronic illnesses and diseases may be tied to food additives and other chemicals that Americans are being exposed to. He has labeled the country's food supply 'poisoned.' The Associated Press spoke to nutrition experts, who criticized Makary for his remarks, arguing that it's overly simplistic to blame ultraprocessed foods for chronic diseases in the U.S.
After the U.S. Supreme Court overturned Roe v. Wade in 2022, Makary appeared on Fox News, where he claimed that fetuses between 15 and 20 weeks of gestation 'will actually resist the instruments of abortion.' Reproductive rights advocates slammed Makary's comments, accusing him of spreading disinformation.
Read More: The Powers Trump's Nominees Will Have Over Abortion
If confirmed as the commissioner of the FDA, Makary would have significant influence over the abortion medication mifepristone, which the FDA approved to be used for abortions more than 20 years ago. The Biden Administration made efforts to increase access to the medication, but reproductive rights advocates are concerned that Makary, if confirmed, could roll back those efforts and restrict access to the drug.
During the COVID-19 pandemic, Makary called the FDA 'broken,' accusing it of being 'mired in politics and red tape.' He claimed that the agency needed 'fresh leadership' that would 'promote scientific advancement, not hinder it.'
He has also accused the nation's leading health agencies of not paying enough attention to chronic diseases, claiming without evidence that 'the greatest perpetrator of misinformation has been the United States government with the food pyramid.'
Contact us at letters@time.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
an hour ago
- Hamilton Spectator
New disputes emerge ahead of US-China trade talks in London
BEIJING (AP) — U.S.-China trade talks in London this week are expected to take up a series of fresh disputes that have buffeted relations, threatening a fragile truce over tariffs. Both sides agreed in Geneva last month to a 90-day suspension of most of the 100%-plus tariffs they had imposed on each other in an escalating trade war that had sparked fears of recession . Since then, the U.S. and China have exchanged angry words over advanced semiconductors that power artificial intelligence, 'rare earths' that are vital to carmakers and other industries, and visas for Chinese students at American universities. President Donald Trump spoke at length with Chinese leader Xi Jinping by phone last Thursday in an attempt to put relations back on track. Trump announced on social media the next day that trade talks would be held on Monday in London. Technology is a major sticking point The latest frictions began just a day after the May 12 announcement of the Geneva agreement to 'pause' tariffs for 90 days. The U.S. Commerce Department issued guidance saying the use of Ascend AI chips from Huawei , a leading Chinese tech company, could violate U.S. export controls. That's because the chips were likely developed with American technology despite restrictions on its export to China, the guidance said. The Chinese government wasn't pleased . One of its biggest beefs in recent years has been over U.S. moves to limit the access of Chinese companies to technology, and in particular to equipment and processes needed to produce the most advanced semiconductors. 'The Chinese side urges the U.S. side to immediately correct its erroneous practices,' a Commerce Ministry spokesperson said. U.S. Commerce Secretary Howard Lutnick wasn't in Geneva but will join the talks in London. Analysts say that suggests at least a willingness on the U.S. side to hear out China's concerns on export controls . China shows signs of easing up on rare earths One area where China holds the upper hand is in the mining and processing of rare earths . They are crucial for not only autos but also a range of other products from robots to military equipment. The Chinese government started requiring producers to obtain a license to export seven rare earth elements in April. Resulting shortages sent automakers worldwide into a tizzy. As stockpiles ran down, some worried they would have to halt production. Trump, without mentioning rare earths specifically, took to social media to attack China. 'The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US,' Trump posted on May 30. The Chinese government indicated Saturday that it is addressing the concerns, which have come from European companies as well. A Commerce Ministry statement said it had granted some approvals and 'will continue to strengthen the approval of applications that comply with regulations.' The scramble to resolve the rare earth issue shows that China has a strong card to play if it wants to strike back against tariffs or other measures. Plan to revoke student visas adds to tensions Student visas don't normally figure in trade talks, but a U.S. announcement that it would begin revoking the visas of some Chinese students has emerged as another thorn in the relationship. China's Commerce Ministry raised the issue when asked last week about the accusation that it had violated the consensus reached in Geneva. It replied that the U.S. had undermined the agreement by issuing export control guidelines for AI chips, stopping the sale of chip design software to China and saying it would revoke Chinese student visas. 'The United States has unilaterally provoked new economic and trade frictions,' the ministry said in a statement posted on its website. U.S. Secretary of State Marco Rubio said in a May 28 statement that the United States would 'aggressively revoke visas for Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields.' More than 270,000 Chinese students studied in the U.S. in the 2023-24 academic year. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

USA Today
an hour ago
- USA Today
Three ways the Trump-Musk feud revealed the GOP's twisted hypocrisy
Three ways the Trump-Musk feud revealed the GOP's twisted hypocrisy | Opinion There's no other takeaway from this other than: We were happy to pay Musk whatever he wanted as long as he loved Trump, but the minute he stopped loving Trump, we can easily stop paying him. Show Caption Hide Caption 'Two big egos.' Americans not surprised by Trump-Musk feud Americans across the country say they're not surprised by the public feud between President Donald Trump and Tesla CEO Elon Musk. Aside from being globally cathartic, the all-too-predictable breakup of President Donald Trump's unquenchable ego and Elon Musk's immense sense of self-importance pulled the dressing-room curtain back on the Republican Party. And what we saw was both cringeworthy and indecent. Or as I like to call it, the Republican Party. Here are three things this episode of 'Real Annoying Billionaires of Washington, DC' taught us about the conservatives who excitedly welcomed Musk – and his money – into politics: 1. Trump and GOP used taxpayers' money to purchase Elon Musk's support As the president and the weirdo billionaire hurled insults at each other on June 5, Trump posted this threat: 'The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts.' Gee, I wonder who, up until June 5, was helping Musk grease the wheels to line up 'Billions and Billions of Dollars' in additional government contracts? As The New York Times reported in March: 'Within the Trump administration's Defense Department, Elon Musk's SpaceX rocketry is being trumpeted as the nifty new way the Pentagon could move military cargo rapidly around the globe. In the Commerce Department, SpaceX's Starlink satellite internet service will now be fully eligible for the federal government's $42 billion rural broadband push, after being largely shut out during the Biden era. … And at the Federal Aviation Administration and the White House itself, Starlink satellite dishes have recently been installed, to expand federal government internet access.' Opinion: Musk erupts, claims Trump is in the Epstein files. Who could've seen this coming? How quickly Trump went from filling Musk's coffers to repay him for his support and campaign contributions to suggesting Musk's contracts were, in fact, a form of government waste and fraud. (I mean … they are a form of government waste and fraud, but not in the way Trump was suggesting.) There's no other takeaway from this other than: We were happy to pay Musk whatever he wanted as long as he loved Trump, but the minute he stopped loving Trump, we can easily stop paying him. I think there's a word for that. 2. Elon Musk, despite all the tush-kissing, never liked or respected Donald Trump Musk's swift about-face on Trump shows what many of us have long suspected: Republicans or Republicans-of-convenience like Musk don't actually like or respect Trump. On Feb. 7, Musk posted on social media: 'I love @realDonaldTrump as much as a straight man can love another man.' On June 5, Musk posted: '@realDonaldTrump is in the Epstein files. That is the real reason they have not been made public. Have a nice day, DJT!' Going from 'I love you, man' to 'I'm alleging you're connected to a notorious sex offender who was facing child sex trafficking charges before he died of suicide in jail' is quite a journey. And it implies that Musk saw Trump for what he is: a useful, loathsome fool. Opinion: Who would want to have babies under a Trump administration? Not me. The minute Trump became not useful to Musk, he sang his truth, something I'd bet most Republicans would do if they had untold wealth and didn't have to worry much about repercussions. That tells you all you need to know about the modern-day GOP – liars boosting a lout in their own self-interest. 3. DOGE was nonsense, and Republicans never really liked Musk For all its fanfare, the U.S. Department of Government Efficiency that Musk oversaw accomplished precious little cost-cutting while inflicting massive harm on America's global reputation, the lives of people reliant on U.S. aid, and the overall functioning of the federal government. Republicans knew this yet still tripped over themselves to toss roses at Musk's feet, hailing him as some kind of genius/savior. They wanted his money, and they wanted the disinformation cannon that comes with his right-wing social media platform. But when Musk grew wise to what Republican lawmakers were doing with the One Big Beautiful Bill Act – a deficit-ballooning monstrosity – he turned on his handmaidens and his former love, President Trump. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. So Trump, of course, called him crazy. Which begs the question: Why were you letting a crazy person access Americans' most private data and demolish the federal workforce? And are you now going to … you know … make sure the guy you think is crazy didn't do something catastrophically bad? Congressional Republicans had to pick a side, and they've largely stepped into Trump's arms, knowing Musk may well be disliked even more than the sitting president. The Washington Post reported June 6: 'Across the government, the Trump administration is scrambling to rehire many federal employees dismissed under DOGE's staff-slashing initiatives after wiping out entire offices, in some cases imperiling key services such as weather forecasting and the drug approval process.' Translation: Musk's DOGE nonsense was for naught, an attempt to fluff a billionaire's ego while cloaking the high-spending, deficit-raising moves Republicans were going to make all along. There's a sucker born every minute, and two Republicans to take 'em. Follow USA TODAY columnist Rex Huppke on Bluesky at @ and on Facebook at


Newsweek
an hour ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.